These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23826758)

  • 1. The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices.
    Vogler S; Zimmermann N; Habl C; Mazag J
    Cost Eff Resour Alloc; 2013 Jul; 11(1):15. PubMed ID: 23826758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System.
    Anggriani Y; Ramadaniati HU; Sarnianto P; Pontoan J; Suryawati S
    Value Health Reg Issues; 2020 May; 21():1-8. PubMed ID: 31634791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014.
    Hamzah NM; Perera PN; Rannan-Eliya RP
    BMC Health Serv Res; 2020 Jun; 20(1):509. PubMed ID: 32503539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
    Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
    BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prices people pay for medicines in Zimbabwe.
    Gavaza P; Simoyi T; Makunike B; Maponga CC
    Cent Afr J Med; 2009; 55(1-4):14-9. PubMed ID: 21977842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
    Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
    Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
    Morgan SG; Vogler S; Wagner AK
    Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on variations in price of prescription medicines in Thailand.
    Burapadaja S; Kawasaki N; Kittipongpatana O; Ogata F
    Yakugaku Zasshi; 2007 Mar; 127(3):515-26. PubMed ID: 17329937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
    Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
    PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of medicine procurement prices in the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA).
    Ewen M; Al Sakit M; Saadeh R; Laing R; Vialle-Valentin C; Seita A; Bunders J
    J Pharm Policy Pract; 2014; 7(1):13. PubMed ID: 25379183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all.
    Kotwani A
    BMC Health Serv Res; 2013 Jul; 13():285. PubMed ID: 23885985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.